The Role of Adjuvant Hormonal Treatment after Surgery for Localized High-Risk Prostate Cancer: Results of a Matched Multiinstitutional Analysis
暂无分享,去创建一个
M. Graefen | A. Briganti | R. Karnes | B. Tombal | C. Scholz | S. Kneitz | H. V. Van Poppel | M. Spahn | J. Walz | P. Gontero* | S. Joniau | C. Bangma | Chao-Yu Hsu | D. Frohneberg | B. Kneitz | M. Schubert | P. V. Van Cangh | P. Bader | G. Marchioro | F. Schröder | R. Karnes | P. Gontero | F. Schröder | Claus-Jü rgen Scholz
[1] E. Antonarakis,et al. Long‐term overall survival and metastasis‐free survival for men with prostate‐specific antigen‐recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database , 2011, BJU international.
[2] I. Thompson,et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] B. Tombal,et al. Cancer Management and Research Dovepress Cardiovascular Risk during Hormonal Treatment in Patients with Prostate Cancer , 2022 .
[4] B. Tombal,et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. , 2010, European urology.
[5] M. Spahn,et al. Long-Term Outcome of Patients with High-Risk Prostate Cancer following Radical Prostatectomy and Stage-Dependent Adjuvant Androgen Deprivation , 2010, Urologia Internationalis.
[6] C. Scholz,et al. Expression of microRNA‐221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence , 2009, International Journal of Cancer.
[7] E. Messing,et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. , 2009, The Journal of urology.
[8] S. Boorjian,et al. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. , 2008, The Journal of urology.
[9] E. Klein,et al. The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival. , 2008, The Journal of urology.
[10] D. Grignon,et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] P. Scardino,et al. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. , 2007, The Journal of urology.
[12] T. H. van der Kwast,et al. The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. , 2006, European urology.
[13] P. Scardino,et al. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. , 2006, The Journal of urology.
[14] Jorge Yao,et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. , 2006, The Lancet. Oncology.
[15] M. Piérart,et al. Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911). , 2005, European journal of cancer.
[16] Alan W Partin,et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. , 2005, JAMA.
[17] William J Catalona,et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. , 2004, The Journal of urology.
[18] Jacques Bernier,et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.
[19] Z. Petrovich,et al. Comparison of surgery alone with surgery and adjuvant radiotherapy for pT3N0 prostate cancer , 2002, BJU international.
[20] E. Bergstralh,et al. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. , 2001, The Journal of urology.
[21] M Bolla,et al. EAU guidelines on prostate cancer. , 2001, European urology.
[22] D. Grignon,et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] W. Marsden. I and J , 2012 .
[24] Thomas Wiegel,et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. , 2011, European urology.
[25] T. Roskams,et al. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. , 2007, European urology.